Novartis AG salvaged a win, gaining conditional FDA approval for Farydak (panobinostat), the first histone deacetylase inhibitor (HDAC) approved to treat patients with multiple myeloma (MM), despite an advisory committee's concerns that the drug's benefit could outweigh its risks in certain contexts.